Pfizer Reveals Phase 3 Results For Vepdegestrant In Advanced Breast Cancer Treatment
31/5 16:38
(RTTNews) - Arvinas Inc. (ARVN) and Pfizer Inc. (PFE) announced detailed results from the Phase 3 VERITAC-2 clinical trial evaluating vepdegestrant monotherapy versus fulvestrant in adults with estrogen receptor-positive, human epidermal growth factor receptor 2-negative (ER+/HER...